Clinical Trials
916 trialsMISOGLIO
University Hospital, Bordeaux
Study of Pamiparib in Newly Diagnosed and rGBM
St. Joseph's Hospital and Medical Center, Phoenix
Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour
Rigshospitalet, Denmark
LEAP-005
Merck Sharp & Dohme LLC
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
POSEIDON
Centre Antoine Lacassagne
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Cedars-Sinai Medical Center
STEMRI
Institut Claudius Regaud
STERIMGLI
Institut Claudius Regaud
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NaviFUS Corporation
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Waikato Hospital
JL15003
Jecho Biopharmaceuticals Co., Ltd.
CITADEL-123
Ariceum Therapeutics GmbH
NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
Medical College of Wisconsin
EF-32
NovoCure Ltd.
UFGAG
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
University of California, San Francisco
DENDR1
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
GLAD
Wake Forest University Health Sciences
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
UC-GlioFET
University of California, San Francisco
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
University of California, Davis
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
ERROR
Maastricht Radiation Oncology
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
CureVac
GEINOCANN
Grupo Español de Investigación en Neurooncología
Feasibility of Individualized Therapy for Recurrent Glioblastoma
University of California, San Francisco
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
Thomas Jefferson University
INDYGO
University Hospital, Lille
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
REGOMA-2
Istituto Oncologico Veneto IRCCS
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
GLIOPLAK
Centre Henri Becquerel
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
SupraGlio-AI
Hospital del Rio Hortega
EVA DOPA
Centre Hospitalier Universitaire de Nīmes
FET-TREAT
Sunnybrook Health Sciences Centre
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
Mundipharma Research Limited
DOSINDYGO
University Hospital, Lille
ROSALIE
Enterome